Murali Gururajan
  • Uro-Oncology Research Program, Department of Medicine, Samuel Oschin Comprehensive Cancer Institute, Cedars-Sinai Medical Center, USA
Research fields
  • Cancer biology
Personal information


Ph.D in Immunology & Toxicology, University of Kentucky, Lexington, KY, USA, 2006

Current position

Senior Research Investigator, Immuno-Oncology Discovery, Bristol-Myers Squibb Company, Princeton, USA


  1. Posadas, E. M., Ahmed, R. S., Karrison, T., Szmulewitz, R. Z., O'Donnell, P. H., Wade, J. L., 3rd, Shen, J., Gururajan, M., Sievert, M. and Stadler, W. M. (2016). Saracatinib as a metastasis inhibitor in metastatic castration-resistant prostate cancer: A University of Chicago Phase 2 Consortium and DOD/PCF Prostate Cancer Clinical Trials Consortium Study. Prostate 76(3): 286-293.
  2. Josson, S., Chung, L. W. and Gururajan, M. (2015). microRNAs and Prostate Cancer. Adv Exp Med Biol 889: 105-118.
  3. Gururajan, M., Cavassani, K. A., Sievert, M., Duan, P., Lichterman, J., Huang, J. M., Smith, B., You, S., Nandana, S., Chu, G. C., Mink, S., Josson, S., Liu, C., Morello, M., Jones, L. W., Kim, J., Freeman, M. R., Bhowmick, N., Zhau, H. E., Chung, L. W. and Posadas, E. M. (2015). SRC family kinase FYN promotes the neuroendocrine phenotype and visceral metastasis in advanced prostate cancer. Oncotarget 6(42): 44072-44083.
  4. Gururajan, M., Josson, S. and Chung, L. W. (2015). Targeting the tumor-stromal-immune cell axis. Oncoscience 2(9): 743-744.
  5. Josson, S., Gururajan, M., Sung, S. Y., Hu, P., Shao, C., Zhau, H. E., Liu, C., Lichterman, J., Duan, P., Li, Q., Rogatko, A., Posadas, E. M., Haga, C. L. and Chung, L. W. (2015). Stromal fibroblast-derived miR-409 promotes epithelial-to-mesenchymal transition and prostate tumorigenesis. Oncogene 34(21): 2690-2699.
  6. Gururajan, M., Josson, S., Chu, G. C., Lu, C. L., Lu, Y. T., Haga, C. L., Zhau, H. E., Liu, C., Lichterman, J., Duan, P., Posadas, E. M. and Chung, L. W. (2014). miR-154* and miR-379 in the DLK1-DIO3 microRNA mega-cluster regulate epithelial to mesenchymal transition and bone metastasis of prostate cancer. Clin Cancer Res 20(24): 6559-6569.
  7. Josson, S., Gururajan, M., Hu, P., Shao, C., Chu, G. Y., Zhau, H. E., Liu, C., Lao, K., Lu, C. L., Lu, Y. T., Lichterman, J., Nandana, S., Li, Q., Rogatko, A., Berel, D., Posadas, E. M., Fazli, L., Sareen, D. and Chung, L. W. (2014). miR-409-3p/-5p promotes tumorigenesis, epithelial-to-mesenchymal transition, and bone metastasis of human prostate cancer. Clin Cancer Res 20(17): 4636-4646.
  8. Gururajan, M., Sindhava, V. J., Bondada, S. (2014) B Cell Tolerance in Health and Disease. Antibodies 3: 116-129.
  9. Josson, S., Matsuoka, Y., Gururajan, M., Nomura, T., Huang, W. C., Yang, X., Lin, J. T., Bridgman, R., Chu, C. Y., Johnstone, P. A., Zayzafoon, M., Hu, P., Zhau, H., Berel, D., Rogatko, A. and Chung, L. W. (2013). Inhibition of beta2-microglobulin/hemochromatosis enhances radiation sensitivity by induction of iron overload in prostate cancer cells. PLoS One 8(7): e68366.
  10. Gururajan, M., Posadas, E. M. and Chung, L. W. (2012). Future perspectives of prostate cancer therapy. Transl Androl Urol 1(1): 19-32.
  11. Josson, S., Nomura, T., Lin, J. T., Huang, W. C., Wu, D., Zhau, H. E., Zayzafoon, M., Weizmann, M. N., Gururajan, M. and Chung, L. W. (2011). beta2-microglobulin induces epithelial to mesenchymal transition and confers cancer lethality and bone metastasis in human cancer cells. Cancer Res 71(7): 2600-2610.
  12. Gururajan, M., Haga, C. L., Das, S., Leu, C. M., Hodson, D., Josson, S., Turner, M. and Cooper, M. D. (2010). MicroRNA 125b inhibition of B cell differentiation in germinal centers. Int Immunol 22(7): 583-592.
  13. Gururajan, M., Simmons, A., Dasu, T., Spear, B. T., Calulot, C., Robertson, D. A., Wiest, D. L., Monroe, J. G. and Bondada, S. (2008). Early growth response genes regulate B cell development, proliferation, and immune response. J Immunol 181(7): 4590-4602.
  14. Gururajan, M., Dasu, T., Shahidain, S., Jennings, C. D., Robertson, D. A., Rangnekar, V. M. and Bondada, S. (2007). Spleen tyrosine kinase (Syk), a novel target of curcumin, is required for B lymphoma growth. J Immunol 178(1): 111-121.
  15. Gururajan, M., Jacob, J. and Pulendran, B. (2007). Toll-like receptor expression and responsiveness of distinct murine splenic and mucosal B-cell subsets. PLoS One 2(9): e863.
  16. Gururajan, M., Jennings, C. D. and Bondada, S. (2006). Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma. J Immunol 176(10): 5715-5719.
  17. Gururajan, M., Chui, R., Karuppannan, A. K., Ke, J., Jennings, C. D. and Bondada, S. (2005). c-Jun N-terminal kinase (JNK) is required for survival and proliferation of B-lymphoma cells. Blood 106(4): 1382-1391.
We use cookies on this site to enhance your user experience. By using our website, you are agreeing to allow the storage of cookies on your computer.